Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva ...

It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...

Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.

The global chronic wound care market is poised for significant growth, with a projected rise at a Compound Annual Growth Rate (CAGR) of 3.8% from 2023 to 2033. The market value is forecasted to ...